<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPathology</journal-id><journal-title-group><journal-title>Open Journal of Pathology</journal-title></journal-title-group><issn pub-type="epub">2164-6775</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpathology.2024.141003</article-id><article-id pub-id-type="publisher-id">OJPathology-130783</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Colon: A Case Report
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Amira</surname><given-names>Mohammad</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Azah</surname><given-names>Syahrina Alias</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Department of Pathology, Hospital Sultanah Aminah Johor Bahru, Johor, Malaysia</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>12</month><year>2023</year></pub-date><volume>14</volume><issue>01</issue><fpage>16</fpage><lpage>24</lpage><history><date date-type="received"><day>12,</day>	<month>December</month>	<year>2023</year></date><date date-type="rev-recd"><day>26,</day>	<month>January</month>	<year>2024</year>	</date><date date-type="accepted"><day>29,</day>	<month>January</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Here we report a rare case of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs). A 51-year-old lady with no known family history of malignancies developed this rare type of malignancy without any active gastrointestinal symptoms. However, during a routine health check, physicians noticed a raised Carcinoembryonic Antigen (CEA) level and the patient subsequently was referred to the surgical department for further management. A colonoscopy and CECT abdomen were done and she was electively admitted for a left hemicolectomy operation for a splenic flexure tumour. The histopathological report revealed the tumour is a case of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) [moderately differentiated adenocarcinoma and neuroendocrine tumour grade 3]. TNM (8th edition, 2016): pT3, pN2 (20/21), pMX. Both resection margins were clear from malignant cells. Colorectal MiNENs, constitute a rare group of gastrointestinal tumours composed of both neuroendocrine and non-neuroendocrine components. Given their non-diagnostic macroscopic features, specific histological features and lack of disease awareness which are responsible for the underestimated incidence and conflicting data. In this case, a multidisciplinary team approach is important in managing patients with this malignancy to achieve the best outcome.
 
</p></abstract><kwd-group><kwd>Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms (MiNENs)</kwd><kwd> Contrast-Enhanced Computed Tomography (CECT)</kwd><kwd> Carcinoembryonic Antigen (CEA)</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>In 2019, malignant epithelial tumours of the colon and rectum were broadly classified by the World Health Organisation (WHO) into Adenocarcinoma, Neuroendocrine tumours, Neuroendocrine carcinoma and MiNEN. Epithelial neoplasms are composed of two different cellular components; neuroendocrine and non-neuroendocrine which are rare entities and may occur in different anatomic sites. In 2010, the World Health Organization (WHO) classification of Digestive System tumours established that mixed neuroendocrine-non- neuroendocrine neoplasms were composed of at least 30% of each component and identified as “Mixed Adenoneuroendocrine Carcinomas (MANEC) [<xref ref-type="bibr" rid="scirp.130783-ref1">1</xref>] . MANEC is defined as a tumour with both morphologically recognizable glandular epithelial and neuroendocrine phenotypes and is also considered a cancer because both elements are malignant. A mixture of squamous cell carcinoma and neuroendocrine elements has also been identified in some oesophagal and anal tumours [<xref ref-type="bibr" rid="scirp.130783-ref2">2</xref>] . Besides gastrointestinal segments, cases of MANEC were also reported to occur in the pancreas, gallbladder, and uterine cervix [<xref ref-type="bibr" rid="scirp.130783-ref3">3</xref>] . In comparison to “MANECs”, the term “MiNENs” is believed to better address the heterogeneous spectrum of possible combinations between neuroendocrine and non-neuroendocrine elements and the variability of morphologies, which are largely determined by the site of origin [<xref ref-type="bibr" rid="scirp.130783-ref4">4</xref>] . The new 5<sup>th</sup> edition WHO classification provided a new framework based on the degree of cellular differentiation creating a group of mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) [<xref ref-type="bibr" rid="scirp.130783-ref5">5</xref>] . For a neoplasm to qualify as MiNEN, both elements of neuroendocrine and non-neuroendocrine should be morphologically and immunohistochemically recognized [<xref ref-type="bibr" rid="scirp.130783-ref6">6</xref>] . The neuroendocrine element should be confirmed by immunohistochemical staining for synaptophysin and/or chromogranin. Ideally and by arbitrary convention, each element should constitute &gt; 30% of neoplasm for the neoplasm to be included within the MiNEN category. To our knowledge, there was only one case of MiNEN reported in Malaysia and it was reported that the said case was a patient who had triple primary malignancy in which one of the malignancies was MiNEN of the colon [<xref ref-type="bibr" rid="scirp.130783-ref7">7</xref>] . Furthermore, evidence from the literature on MiNEN was almost exclusively derived from case reports and retrospective studies. Due to the rarity of this diagnosis, the limited quality of published data, and the use of inconsistent terminology, the epidemiology, prognosis, and best therapeutic management of patients with MiNEN remains unknown. Hence, this case report aims to accumulate the existing evidence on colorectal MiNEN in Malaysia with special attention towards understanding the morphology and clinicopathological features of MiNENs, as definitive diagnosis of MiNEN usually only follows after surgical resection.</p></sec><sec id="s2"><title>2. Case Presentation</title><p>A 51-year-old lady, with underlying dyslipidemia and hypertension was referred to the surgical team to investigate her raised Carcinoembryonic Antigen (CEA). Her CEA level increased to 10 nanograms per millilitre of blood (ng/mL). She was soon investigated for this increased CEA level and subjected to colonoscopy and a few radiological tests. She denies any active gastrointestinal symptoms or any constitutional symptoms. She also denied any family history of cancer. The patient was electively admitted to the surgical ward with no active complaints. She was stable and able to tolerate foods and drinks without any symptoms of intestinal obstruction. A colonoscopy was also done during her admission, which revealed a fungating tumour located 60 cm from the anal verge. She also went for a CECT abdomen (<xref ref-type="fig" rid="fig1">Figure 1</xref>) that revealed a descending colon tumour with few enlarged mesenteric nodes and two hypodense liver lesions. The patient did not experience any surgical complications post-surgery and was discharged home 5 days later. Approximately two weeks post-operation, the patient had her follow-up at our surgical clinic. On examination, the patient’s abdominal wound healed well and she had no active complaints. They had a further discussion with a visiting clinical oncologist regarding the need for any adjuvant chemotherapy. The patient was counselled for adjuvant chemotherapy: 8 cycles of Oxyplatin and Capecitabine (XELOX) for 3 weeks. The adjuvant chemotherapy is planned after two months of operation.</p></sec><sec id="s3"><title>3. Histopathology</title><p>Macroscopic examination of the resected specimen (<xref ref-type="fig" rid="fig2">Figure 2</xref>) revealed a nearly circumscribed, firm and greyish fungating splenic flexure tumour measuring 42 &#215; 25 &#215; 10 mm. Further cross-section of the tumour showed that the tumour has a cream-tan cut surface (<xref ref-type="fig" rid="fig3">Figure 3</xref>) and it is also grossly seen invading beyond</p><p>the Muscularis Propria into the surrounding fat. Both resected margins were far away from the main tumour. No other precursor lesions were seen. A total of 21 lymph nodes were harvested. Hematoxylin and eosin (H&amp;E) stainings of the tumour showed a mixed component of malignant cells composed of 40% carcinomatous (non-neuroendocrine element) and 60% neuroendocrine element (<xref ref-type="fig" rid="fig4">Figure 4</xref>). The non-neuroendocrine element (<xref ref-type="fig" rid="fig5">Figure 5</xref>) is composed of malignant cells arranged in villiform and irregular glandular patterns and they display hyperchromatic nuclei with moderate nuclear pleomorphism and prominent nucleoli (<xref ref-type="fig" rid="fig6">Figure 6</xref>). Mitosis is frequently observed. The neuroendocrine element is composed of malignant cells arranged in clusters and sheets, displaying large</p><p>cells with vesicular nuclei and prominent nucleoli (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Mitosis is frequently observed (19/10 hpf). Extensive lympho-vascular invasion was also identified (<xref ref-type="fig" rid="fig8">Figure 8</xref>). The malignant cells infiltrate beyond the Muscularis Propria into surrounding pericolic fat. Multiple lymph nodes were harvested and 20 lymph nodes out of a total of 21 lymph nodes showed evidence of metastasis (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Immunohistochemical stains showed that the tumour cells of the</p><p>neuroendocrine element were positive for Synaptophysin (<xref ref-type="fig" rid="fig1">Figure 1</xref>0(a)), Chromogranin A (<xref ref-type="fig" rid="fig1">Figure 1</xref>0(b)) and CD56 (<xref ref-type="fig" rid="fig1">Figure 1</xref>0(c)). The Ki 67 proliferative index is about 30 to 40% (<xref ref-type="fig" rid="fig1">Figure 1</xref>0(d)).</p></sec><sec id="s4"><title>4. Discussion</title><p>Colorectal MiNEN is an uncommon tumour to be encountered. The true prevalence of MiNEN is unknown, especially in Malaysia. Overall, the only available evidence is from case reports and retrospective studies. Regarding the best choice of treatment in cases of MiNEN, with the absence of good data from clinical trials, the management depends on which of the two components shows the most aggressive histological morphology. If the neuroendocrine part appears more aggressive, MiNENs are generally treated according to the standard management used for neuroendocrine carcinoma counterpart. If the non-neuroen- docrine counterpart appears more aggressive, some clinicians might be treating</p><p>these patients according to the standard epithelial tumours of the colon. However, both approaches are not supported by any evidence from prospective randomised trials [<xref ref-type="bibr" rid="scirp.130783-ref8">8</xref>] . In this patient’s case, the clinician opted for adjuvant chemotherapy given the tumour’s neuroendocrine carcinoma counterpart appeared more aggressive.</p></sec><sec id="s5"><title>Acknowledgements</title><p>We would like to thank the lady for allowing us to share her case for educational purposes and also thank Dr. Azah Syahrina, a Histopathologist in Hospital Sultanah Aminah, Johor Bahru, for her wisdom, guidance and advice in the preparation of this case report.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Mohammad, A. and Alias, A.S. (2024) Mixed Neuroendocrine-Non-Neuroendocrine Neoplasm (MiNEN) of the Colon: A Case Report. Open Journal of Pathology, 14, 16-24. https://doi.org/10.4236/ojpathology.2024.141003</p></sec></body><back><ref-list><title>References</title><ref id="scirp.130783-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Silva, D.J., Vaz, A.P. and Mesquita, A. (2021) Rectal Mixed Adenoneuroendocrine Carcinoma: A Case Report. Medicine, 100, e27348. https://doi.org/10.1097/MD.0000000000027348</mixed-citation></ref><ref id="scirp.130783-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Assarzadegan, N. and Montgomery, E. (2021) What Is New in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing. Archives of Pathology &amp; Laboratory Medicine, 145, 664-677. https://doi.org/10.5858/arpa.2019-0665-RA</mixed-citation></ref><ref id="scirp.130783-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gurzu, S., Kadar, Z., Bara, T., Bara, T.J., Tamasi, A., Azamfirei, L. and Jung, I. (2014) Mixed Adenoneuroendocrine Carcinoma of the Gastrointestinal Tract: Report of Two Cases. World Journal of Gastroenterology: WJG, 21, 1329-1333. https://doi.org/10.3748/wjg.v21.i4.1329</mixed-citation></ref><ref id="scirp.130783-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">La Rosa, S., Sessa, F. and Uccella, S. (2016) Mixed Neuroendocrine-Nonneuroen-docrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms. Endocrine Pathology, 27, 284-311. https://doi.org/10.1007/s12022-016-9432-9</mixed-citation></ref><ref id="scirp.130783-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Nagtegaal, I.D., Odze, R.D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., Washington, K.M., Carneiro, F. and Cree, I.A. (2020) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188. https://doi.org/10.1111/his.13975</mixed-citation></ref><ref id="scirp.130783-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C., Yang, N., Chen, C., Huang, L., Yan, T., Yang, X., Li, N., Zhang, S., Yang, P. and Feng, Z. (2021) Clinicopathological Features and Prognostic Factors Associated with Gastroenteropancreatic Mixed Neuroendocrine Non-Neuroendocrine neoplasms in Chinese Patients. World Journal of Gastroenterology, 27, 624-640. https://doi.org/10.3748/wjg.v27.i7.624</mixed-citation></ref><ref id="scirp.130783-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mariapan, K., Yee, L.F., Jasmani, A.H., Osman, M.F. and Dass, A. (2022) The Unfortunate Case of Triple Primary Malignancies. Malaysian Journal of Medicine and Health Sciences, 18, 31-33. https://doi.org/10.47836/mjmhs.18.s13.10</mixed-citation></ref><ref id="scirp.130783-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Frizziero, M., Chakrabarty, B., Nagy, B., Lamarca, A., Hubner, R. A., Valle, J.W. and McNamara, M.G. (2019) Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis. Journal of Clinical Medicine, 9, 273. https://doi.org/10.3390/jcm9010273</mixed-citation></ref></ref-list></back></article>